SEARCH

SEARCH BY CITATION

References

  • 1
    Talley NJ, Colin-Jones D, Koch KL, et al.Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 14560.
  • 2
    Jones RH, Lydeard SE, Hobbs FDR, et al.Dyspepsia in England and Scotland. Gut 1990; 31: 4015.
  • 3
    Talley NJ, Stanghellini V, Heading RC, et al.Functional gastroduodenal disorders. Gut 1999; 45(Suppl. II): II3742.
  • 4
    Talley NJ, Phillips SF. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med 1988; 108: 86579.
  • 5
    Mearin F, Malagelada JR. Upper gut motility and perception in functional dyspepsia. Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 61521.
  • 6
    Blum A, Talley NJ, O'Marian C, et al.Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 187581.
  • 7
    Talley NJ. AGA Technical review. Evaluation of dyspepsia. Gastroenterology 1998; 114: 58295.
  • 8
    Read NW, Khan MI. Gut sensitivity in functional dyspepsia. Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 6225.
  • 9
    Kellow JE. Organic causes of dyspepsia, and discriminating functional from organic dyspepsia. Ballieres Clin Gastroenterol 1998; 12: 47787.
  • 10
    Kellow JE, Delvaux M, Azpiroz F, et al.Principles of applied neurogastroenterology: physiology/motility-sensation. Gut 1999; 45(Suppl. II): II1724.
  • 11
    Drossman DA. Psychosocial factors in functional dyspepsia. Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 6027.
  • 12
    Nyren O. Functional dyspepsia: is gastric acid and/or Helicobacter pylori infection involved in the aetiology? Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 60814.
  • 13
    Hveem K, Svebak S, Hausken T, et al.Effect of mental stress and cisapride on autonomic nerve functions in functional dyspepsia. Scand J Gastroenterol 1998; 33: 1237.
  • 14
    Bennet EJ, Piesse C, Palmer K, et al.Functional gastrointestinal disorders: psychological, social and somatic features. Gut 1998; 42: 41420.
  • 15
    Waldron B, Cullen PT, Kumar R, et al.Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32: 24651.
  • 16
    Tack J, Piessevaux H, Coulie B, et al.Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 15867.
  • 17
    Berstad A, Hausken T, Gilja OH, et al.Imaging studies in dyspepsia. Eur J Surg Suppl 1998; 582: 429.
  • 18
    Hausken T, Gilja OH, Undeland KA, et al.Timing of postprandial dyspeptic symptoms and transpyloric passage of gastric contents. Scand J Gastroenterol 1998; 33: 8227.
  • 19
    Bradette M, Pare P, Douville P, Morin A. Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone. Dig Dis Sci 1991; 36: 528.
  • 20
    Stanghellini V, Tosetti C, Paternico A, et al.Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110: 103642.
  • 21
    Al-Qourain A, Larbi EB, Al-Shedoki F. A double blind, randomised, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. Scand J Gastroenterol 1995; 30: 5314.
  • 22
    Hausken T, Berstad A. Cisapride treatment of patients with non-ulcer dyspepsia and erosive pre-pyloric changes. A double blind, placebo controlled trial. Scand J Gastroenterol 1992; 27: 2137.
  • 23
    Sarin SK, Sharma P, Chawla YK, et al.Clinical trial on the effect of domperidone on non-ulcer dyspepsia. Indian J Med Res 1986; 83: 6238.
  • 24
    Dobrilla G, Comberlato M, Steele A, et al.Drug treatment of functional dyspepsia. J Clin Gastroenterol 1989; 11(2): 16977.
  • 25
    Kellow JE, Cowan H, Shuter B, et al.Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995; 9: 15360.
  • 26
    Champion MC, MacCannell KL, Thomson ABR, et al.A double blind randomised study of cisapride in the treatment of non-ulcer dyspepsia. Can J Gastroenterol 1997; 11: 12733.
  • 27
    Yeoh KG, Kang JY, Tay HH, et al.Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial. J Gastroenterol Hepatol 1997; 12: 138.
  • 28
    Finney JS, Kinnersley N, Hughes M, et al.Meta analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26 (4): 31220.
  • 29
    DeGroot GH, DeBoth PSM. Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double blind study. Aliment Pharmacol Ther 1997; 11: 1939.
  • 30
    Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 36874.
    Direct Link:
  • 31
    Kanaizumi T, Nakano H, Matsui Y, et al.Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur Clin Pharm 1991; 41: 3357.
  • 32
    Kato S, Morie T, Kon T, et al.Novel benzamides as selective and potent gastric prokinetic agents. 2. Synthesis and structure–activity relationships of 4-amina-5-chlor-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl) benzamide citrate (AS-4370) and related compounds. J Med Chem 1991; 34: 61624.
  • 33
    Yamada M, Hongo M, Okuno Y, et al.Effect of AS-4370 on gastric motility in patients with diabetic autonomic neuropathy. J Smooth Muscle Res (Jpn) 1992; 28: 538.
  • 34
    Yoshida N, Omyoya H, Furukawa O, et al.Pharmacological studies on mosapride citrate (AS-4370), a gastroprokinetic agent — Comparison with cisapride and metoclopramide. Jpn Pharmacol Ther 1993; 21: 24964.
  • 35
    Yoshida N, Ito T. AS-4370, a new gastrokinetic agent, is a partial 5-hydroxy-tryptamine 4 receptor agonist in the gut. Neurogastroenterol & Motility 1994; 6(3): 197204.
  • 36
    Iyaku R, Miwa T, Harasawa S, et al.Dose finding study of AS-4370 in patients with chronic gastritis. J Clin Ther Med 1995; 11: 56588.
  • 37
    Junghard O, Lauritsen K, Talley NJ, et al.Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia. Eur J Surg Suppl 1998; 583: 10611.
  • 38
    Holtman G, Talley NJ. Functional dyspepsia. Current treatment and recommendations. Drugs 1993; 45: 91830.
  • 39
    Veldhuyzen van Zanten SJO, Cleary C, Talley NJ, et al.Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91: 66071.
  • 40
    Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, et al.Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. II): II6977.
  • 41
    Thompson WG, Longstreth GF, Drossman DA, et al.Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. II): II4347.
  • 42
    Van Ganse W, Van Damme L, Van de Mierop L, et al.Chronic dyspepsia: Double blind treatment with domperidone (R33 812) or a placebo. A multicentre therapeutic evaluation. Curr Ther Res 1987; 23: 695701.
  • 43
    Behkti A, Rutgeerts L. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgrad Med J 1979; 55(Suppl. 1): 302.
  • 44
    Van de Mierop L, Rutgeerts L, Van Den Langenbergh B, et al.Oral domperidone in chronic postprandial dyspepsia. Digestion 1979; 19: 24450.
  • 45
    Hannon R. Efficacy of cisapride in patients with non-ulcer dyspepsia. Curr Ther Res 1987; 42: 81421.
  • 46
    Chung JM. Cisapride in chronic dyspepsia: Result of a double blind, placebo-controlled trial. Scand J Gastroenterol 1993; 28(Suppl. 195): 114.
  • 47
    Rösch W. Cisapride in non-ulcer dyspepsia. Scand J Gastroenterol 1987; 22: 1614.
  • 48
    Rösch W. Efficacy of cisapride in the treatment of epigastric pain and concomitant symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1989; 24(Suppl. 165): 548.
  • 49
    DeNutte N, VanGanse W, Witterhulge M, et al.Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride. Clin Ther 1989; 11: 628.
  • 50
    Francois I, De Nutte N. Non-ulcer dyspepsia: effect of the gastrointestinal prokinetic drug cisapride. Curr Ther Res 1987; 41: 8917.
  • 51
    Talley NJ. Functional gastroduodenal disorders. In: Drossman DA, ed. The Functional Gastrointestinal Disorders — Diagnosis, Pathophysiology, and Treatment. Little, Brown and Co., 1994: 71–114.
  • 52
    Talley NJ. Optimal design of treatment trials. In: Drossman DA, ed. The Functional Gastrointestinal Disorders — Diagnosis, Pathophysiology, and Treatment. Little, Brown and Co., 1994: 265–310.